Advertisement

Topics

Fibrocell and Castle Creek Pharmaceuticals Collaborate for Development and Commercialization of FCX-007 Gene Therapy

09:07 EDT 16 Apr 2019 | Speciality Pharma Journal

EXTON, Pa., April 15, 2019 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (Nasdaq: FCSC), a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the completion of a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the …

Original Article: Fibrocell and Castle Creek Pharmaceuticals Collaborate for Development and Commercialization of FCX-007 Gene Therapy

NEXT ARTICLE

More From BioPortfolio on "Fibrocell and Castle Creek Pharmaceuticals Collaborate for Development and Commercialization of FCX-007 Gene Therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...